Search News Archives
Special Offers and Promotions
Conferences | Events
Optibrium and Certara Collaborate on Integration of StarDrop and D360
Optibrium™ and Certara®, developers of software products and services for drug discovery and development, today announced a collaboration to provide their mutual customers with an integrated solution linking Optibrium’s StarDrop™ with Certara’s D360™ platform.
The combination of these two products enables researchers to combine the industry-leading self-service data access and analysis capabilities of D360, with StarDrop’s unique, interactive environment that guides compound selection and design decisions in drug discovery, helping project teams to identify high quality compounds more efficiently.
D360 provides scientific data integration, access, analysis, and visualisation capabilities for early discovery through to the preclinical and clinical phases of drug development. D360 solves both intra and inter-domain research challenges by integrating data from multiple source systems to provide both standard data views and data mining capabilities. In addition, D360 brings context and understanding to the data, enabling scientists to gain deeper insight and make better scientific decisions. Integration with Optibrium’s StarDrop suite enables researchers to seamlessly retrieve their compound data using D360 from within StarDrop’s intuitive environment for viewing and interacting with their data in the context of a discovery project. StarDrop provides a highly visual way to interpret data on compounds and their relationships, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery. The combination of the two platforms further extends their capabilities to reduce the time and cost associated with identifying high quality compounds and new optimisation strategies.
Dr Matthew Segall, CEO of Optibrium, commented: “This latest collaboration demonstrates our commitment to delivering a seamless integration between StarDrop and our users’ data access infrastructure. We’ve responded to feedback from global pharma companies that requested integration between these two platforms be made available in the most user-friendly way. We are pleased at the ease with which this integration has been implemented.”